Because Xtampza ER is not bioequivalent to other oxycodone extended-release products; Monitor patients for possible dosage adjustment; Conversion from other opioids. Discontinue all other around-the clock opioid drugs; There are no established conversion ratios for conversion from other opioids to Xtampza ER defined by clinical trials
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
OxyContin titration and maintenance. 1  Individually titrate to a dosage that provides adequate analgesia and minimizes adverse reactions. 2  Continually re-evaluate pain control, signs and symptoms of opioid withdrawal, and adverse reactions, as well as monitoring for the development of addiction, abuse and misuse.
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
Initial dose. 1  Dosing information is only for children ≥11 yr who are already receiving and tolerating opioids for at least 5 consecutive days, and for the 2 days immediately preceding dosing with OxyContin, patients must be taking a minimum of 20 mg/day of oxycodone or its equivalent.
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
OxyContin is not effective for immediate pain relief (for example in an emergency room). Dosage The initial adult dose of oxycodone is 5mg to 15mg taken orally every 4 to 6 hours.
https://www.diffen.com/difference/OxyContin_vs_Oxycodone
Conversion from other opioids to Xtampza ER. Conversion from other oral oxycodone formulations. Administer one-half of the patient's total daily PO oxycodone dose as q12hr with food; Because Xtampza ER is not bioequivalent to other oxycodone extended-release products; Monitor patients for possible dosage adjustment; Conversion from other opioids to OxyContin or Xtampza ER. 1  Provide immediate-release opioids for breakthrough pain. 2  Monitor patient closely for adverse effects or breakthrough pain during conversion and for several days following. 3  Also see Medscape reference topic - Opioid Equivalents.
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
OxyContin vs Oxycodone comparison. The active ingredient in OxyContin is oxycodone but OxyContin (a brand name derived from 'oxycodone continuous') has a time-release mechanism, which means the drug is released in the body over a period of time and patients have to take the drug less often....
https://www.diffen.com/difference/OxyContin_vs_Oxycodone
As such, it is preferable to underestimate a patient’s 24-hr oral oxycodone requirements and provide rescue medication (eg, immediate-release opioid) than to overestimate the 24-hr oral oxycodone requirements and manage adverse effects; Conversion factors of prior opioid . Oxycodone PO: 1; Hydrocodone PO: 0.9; Hydromorphone PO: 4
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
Xtampza ER Conversion from other oral oxycodone formulations: Administer one-half of the patient's total daily PO oxycodone dose as q12hr with food; because Xtampza ER is not bioequivalent to other oxycodone extended-release products, monitor patients for possible dosage adjustment.
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
Because Xtampza ER is not bioequivalent to other oxycodone extended-release products Monitor patients for possible dosage adjustment Conversion from other opioids to OxyContin or Xtampza ER. Provide immediate-release opioids for breakthrough pain. Monitor patient closely for adverse effects or breakthrough pain during conversion and for several days following.
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321
Oxycodone is a narcotic medication used to relieve moderate to severe pain. OxyContin is a brand of timed-release oxycodone, made by Purdue Pharma, that works for up to 12 hours. The drug is in a class of medications called opioid analgesics; they work by changing the way your brain and nervous system respond to pain.
https://www.everydayhealth.com/drugs/oxycodone
what is oxycodone er
Oxycodone is a narcotic medication used to relieve moderate to severe pain.